Physician profile
Narendra Sankar
NPI 1437313723
$4,831.97
in general payments reported to CMS, 2019-2025
25 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $893 · 2021: $679 · 2022: $1,098 · 2023: $812 · 2024: $427 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,720.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,190.61 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $747.80 | 2019-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $509.42 | 2020-2025 | Amplatzer Piccolo, Jot Dx, Gallant |
| Amgen INC. | $461.22 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $367.00 | 2021-2025 | Qulipta, Linzess |
| Novo Nordisk INC | $352.52 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Esperion Therapeutics, INC. | $175.87 | 2020-2024 | Nexletol |
| Amarin Pharma, INC. | $175.68 | 2019-2022 | |
| Pfizer INC. | $142.14 | 2019-2022 | |
| Allergan, INC. | $128.48 | 2020 | |
| Paratek Pharmaceuticals, INC. | $104.59 | 2024-2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $78.21 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $71.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $53.58 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $38.58 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.73 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.41 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.87 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $28.36 | 2021 | |
| Astellas Pharma US INC | $22.99 | 2023 | Veozah |
| Verity Pharmaceuticals INC. | $22.61 | 2025 | Tlando |
| Alnylam Pharmaceuticals INC. | $22.26 | 2020 | |
| Sumitomo Pharma America, INC. | $20.89 | 2025 | Gemtesa |
| Alexion Pharmaceuticals, INC. | $13.53 | 2020 | |
| Lucid Diagnostics INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narendra Sankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.